|
|
|
|
|||||
|
|
|
Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3.
Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.
The healthcare sector has vastly outperformed the broader market in recent weeks. The S&P 500 Health Care Sector index is up around 5.1% over the past month, while the broader S&P 500 index has climbed just about 2.3%.
The primary factor behind this outperformance is blockbuster drugs. The best-performing healthcare stocks in the sector are drug manufacturers, and they've been on fire of late.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Eli Lilly (NYSE: LLY) had a huge third quarter, and its GLP-1 medication -- tirzepatide, which treats both type 2 diabetes and obesity -- became the best-selling drug on the planet during the quarter. Lilly, the largest company in the sector by market cap, is up 9.1% over the past month.
Johnson & Johnson (NYSE: JNJ) announced on Nov. 17 that it will acquire Halda Therapeutics, a clinical-stage biotechnology company. Halda has a proprietary platform to develop oral, targeted therapies for multiple types of solid tumors, particularly prostate cancer. J&J's stock is up 8.6% over the past month.
AbbVie (NYSE: ABBV) is another hot pharma stock. Sales of its Skyrizi, an immunology drug that treats conditions like psoriasis and arthritis, rose a whopping 46.8% to $4.7 billion during the third quarter. Sales of Rinvoq, a similar immunology drug, climbed 35.3% to nearly $2.2 billion. Management said it believes Rinvoq will hit $11 billion in annual revenue by 2027, and Skyrizi will reach the $20 billion mark. The stock has climbed 4.3% in a month.
And drug giant Merck (NYSE: MRK) is up a whopping 18.2% over the past month. Quarterly sales of Keytruda, its blockbuster cancer drug, rose 10% from the same period a year ago and topped $8 billion for the first time.
Those are a few of the major blockbuster drugs sending healthcare stocks higher, but there are many more.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $521,982!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,137,459!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of December 8, 2025
Matthew Benjamin has positions in Select Sector SPDR Trust-State Street Health Care Select Sector SPDR ETF. The Motley Fool has positions in and recommends AbbVie and Merck. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
| 11 min | |
| 1 hour | |
| 1 hour | |
| 2 hours | |
| 2 hours | |
| 2 hours | |
| 2 hours | |
| 2 hours | |
| 3 hours | |
| 4 hours | |
| 4 hours | |
| 4 hours | |
| 5 hours | |
| 6 hours | |
| 6 hours |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite